NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

This roundtable series looks at the use of CAR T-cell therapy for patients with large B-cell lymphoma and how this is expanding treatment options for these patients in the second-line setting, as discussed by key opinion leaders and participants at virtual live events.

Expanding Second-Line Therapy in B-cell Lymphoma with CAR T-Cell Therapy

Early Relapsed DLBCL Counseling Includes CAR T and Alternative Therapy

Early Relapsed DLBCL Counseling Includes CAR T and Alternative Therapy

August 07, 2025

During a live event, Matthew Lunning, DO, and participants discussed the process of determining if patients with DLBCL should receive second-line CAR T-cell therapy.

Early Relapsed DLBCL Counseling Includes CAR T and Alternative Therapy

Early Relapsed DLBCL Counseling Includes CAR T and Alternative Therapy

August 07, 2025

During a live event, Matthew Lunning, DO, and participants discussed the process of determining if patients with DLBCL should receive second-line CAR T-cell therapy.

$Primary Refractory DLBCL Status Takes on Greater Significance in CAR T Era$

Primary Refractory DLBCL Status Takes on Greater Significance in CAR T Era

During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed DLBCL matters for using second-line CAR T-cell therapy.

Navigating CAR T-Cell Therapy Decisions in Relapsed B-Cell Lymphoma

Navigating CAR T-Cell Therapy Decisions in Relapsed B-Cell Lymphoma

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed or high-risk lymphoma.

Overcoming Caregiver Barriers in CAR T-Cell Therapy Referrals in DLBCL

Overcoming Caregiver Barriers in CAR T-Cell Therapy Referrals in DLBCL

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy caregiver challenges and referral considerations after DLBCL relapse.

CAR T Toxicity Differences Seen in Transplant-Ineligible LBCL

CAR T Toxicity Differences Seen in Transplant-Ineligible LBCL

During a live event, Nathan M. Denlinger, DO, MS, discussed the PILOT and ALYCANTE trials of CAR T-cell therapy in transplant-ineligible B-cell lymphoma.

Examining Impact of Crossover in the TRANSFORM Study of CAR T in LBCL

Examining Impact of Crossover in the TRANSFORM Study of CAR T in LBCL

During a live event, Nathan M. Denlinger, DO, MS, discussed the TRANSFORM trial of lisocabtagene maraleucel in B-cell lymphoma and its crossover design.

Examining Impact of Crossover in the TRANSFORM Study of CAR T in LBCL

Examining Impact of Crossover in the TRANSFORM Study of CAR T in LBCL

During a live event, Nathan M. Denlinger, DO, MS, discussed the TRANSFORM trial of lisocabtagene maraleucel in B-cell lymphoma and its crossover design.

Early Relapsed DLBCL Outcomes Have Changed Drastically Due to CAR T

Early Relapsed DLBCL Outcomes Have Changed Drastically Due to CAR T

During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary refractory or early relapsed DBLCL since the introduction of CAR T-cell therapy.

CAR T-Cells Demonstrate Efficacy, Tolerability in Early-Relapsed DLBCL

CAR T-Cells Demonstrate Efficacy, Tolerability in Early-Relapsed DLBCL

February 20, 2025

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first article of a 2-part series.

Ahmed Discusses Why the Wait for Liso-Cel Is Worth It

Ahmed Discusses Why the Wait for Liso-Cel Is Worth It

During a Case-Based Roundtable® event, Sairah Ahmed, MD, discussed the data behind the use of lisocabtagene maraleucel for patients with diffuse large B-cell lymphoma in the second article of a 2-part series.

Ahmed Discusses Why the Wait for Liso-Cel Is Worth It

Ahmed Discusses Why the Wait for Liso-Cel Is Worth It

During a Case-Based Roundtable® event, Sairah Ahmed, MD, discussed the data behind the use of lisocabtagene maraleucel for patients with diffuse large B-cell lymphoma in the second article of a 2-part series.

CAR T-Cell Therapy Presents a Paradigm Changing Option in DLBCL

CAR T-Cell Therapy Presents a Paradigm Changing Option in DLBCL

During a Case-Based Roundtable® event, Sairah Ahmed, MD, discussed how the burgeoning use of chimeric antigen receptor T-cell therapy presents a paradigm shift in treatment for patients with diffuse large B-cell lymphoma in the first article of a 2-part series.

CAR T-Cell Therapy Broadens Second-Line Treatment in LBCL

CAR T-Cell Therapy Broadens Second-Line Treatment in LBCL

Matthew Lunning, DO, FACP, discusses the use of CAR T-cell therapy lisocabtagene maraleucel in the second-line setting for patients with B-cell lymphoma.

© 2025 MJH Life Sciences^®

All rights reserved.